Market Cap
$31.9B
RMD
RESMED INC
$220.30 ▼ -0.38%
Prev close $221.15Market cap$31.9B
ConsensusHold
12-mo target$250.22 (+13.6%)
▲ Neutral
Analyst conviction 5/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)36 New Institutional Positions14 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on RMD right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Hold (48%)
Inst. Holders
50 funds
Inst. Value
$15.4B
Inst. Activity
36 buys / 14 sells
Insider Activity
$0.00 buy / $13.2M sell
Insider Net $
-$13.2M
Social Sentiment
54° Neutral
SEC Reports
9
Press Releases
2
Congressional
2 trades
Price chart 30d -4.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 earnings
Sep 10, 2026 SEC Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans t
ResMed's CEO and a director sold a combined ~$1.34M in shares over a week, with the CEO's sale following a derivative ex
CLUSTER — Impact 4/10
Sep 8, 2026 Insider
Farrell Michael J. acquired via exercise 4,991 shares
Chairman and CEO @ $146.34 ($730.4K)
Sep 8, 2026 Insider
Farrell Michael J. sold 4,991 shares
Chairman and CEO @ $222.44 ($1.1M)
Sep 2, 2026 Insider
Aug 11, 2026 SEC FARRELL PETER C sold 970 shares
Director @ $234.73 ($227.7K)
ResMed's CEO Michael Farrell and Director Peter Farrell sold a combined $2.83M in open-market shares over a 3-day window
CLUSTER — Impact 2/10
Resmed has agreed to sell its long-term care software business MatrixCare to Frazier Healthcare Partners. The move focus
Impact 4/10
Jun 30, 2026 Inst.
FIRST TRUST ADVISORS LP — ADD
2,278,696 shares ($444.1M)
Analyst ratings buy % -25.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
48% rate it Buy or better · 27 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 15, 2026 | RBC Capital | UPGRADE | Outperform | 55% |
| Aug 31, 2026 | Keybanc | MAINTAIN | Overweight | 52% |
| Aug 19, 2026 | Rothschild & Co | INITIATE | Neutral | 58% |
| Aug 7, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
| Aug 7, 2026 | Piper Sandler | MAINTAIN | Neutral | 54% |
| Aug 7, 2026 | Keybanc | MAINTAIN | Overweight | 52% |
| Aug 7, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | 54% |
| Jul 15, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jul 13, 2026 | Citigroup | DOWNGRADE | Neutral | 55% |
| Jul 10, 2026 | Jefferies | MAINTAIN | Hold | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 9 | 12 | 1 | 1 | 48% | |
| Aug 1, 2026 | 3 | 9 | 11 | 1 | 1 | 48% | |
| Jul 1, 2026 | 4 | 10 | 9 | 1 | 1 | 56% | |
| Jun 1, 2026 | 4 | 11 | 8 | 1 | 1 | 60% | |
| May 1, 2026 | 4 | 12 | 9 | 0 | 1 | 62% | |
| Apr 1, 2026 | 4 | 11 | 9 | 0 | 1 | 60% | |
| Mar 1, 2026 | 4 | 12 | 8 | 0 | 1 | 64% | |
| Feb 1, 2026 | 4 | 12 | 8 | 0 | 1 | 64% |
Price targets
Where 17 covering analysts think RMD trades over the next 12 months.
$250.22 +13.6% upside Buy
Current$220.31 Low$175.00 Median$235.00 High$320.00 17 analysts
$175.00$320.00
Analyst rating Buy· 2.3/5 as of Oct 2, 2026
Social media sentiment mood +25.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
54°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 1 bullish, 2 bearish, 0 mixed, 6 neutral · avg impact 3.9/10.Plus 2 press releases.
NEUTRALCLUSTER4/10
ResMed's CEO and a director sold a combined ~$1.34M in shares over a week, with the CEO's sale follo
Sep 10, 2026
NEUTRALCLUSTER2/10
ResMed's CEO Michael Farrell and Director Peter Farrell sold a combined $2.83M in open-market shares
Aug 11, 2026
BEARISHPRESS-RELEASE5/10
Resmed reports fiscal Q3 2026 EPS of $2.86, a 1.4% miss vs consensus of $2.90. The miss breaks a str
May 19, 2026
NEUTRALCLUSTER3/10
ResMed insiders sold $1.8M in shares over a 7-day period, led by CEO Michael Farrell's $1.13M open-m
Apr 9, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
earnings
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for th
Sep 30, 2026
short_volume
Short Volume: RMD — 66.7% short (0.4M / 0.6M)
Short: 390,365 | Exempt: 0 | TRF Vol: 585,225 | Short Ratio: 66.7% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: RMD — 65.8% short (0.4M / 0.6M)
Short: 372,518 | Exempt: 22 | TRF Vol: 565,739 | Short Ratio: 65.8% | Off-exchange volume (dark pool + OTC)
Sep 15, 2026
short_volume
Short Volume: RMD — 85.5% short (0.5M / 0.6M)
Short: 549,816 | Exempt: 0 | TRF Vol: 642,912 | Short Ratio: 85.5% | Off-exchange volume (dark pool + OTC)
Sep 7, 2026
dark_pool
Dark Pool: RMD — 1.3M shares, 42,409 trades
Week starting 2026-09-07. Total ATS volume: 1,334,622 shares across 42,409 trades.
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $2.67 | $2.62–$2.76 | 4.7% | -0.7% | 1↑ 8↓ | $1.4B | 13 |
| Next Q | $3.03 | $2.93–$3.11 | 7.9% | -0.2% | 6↑ 3↓ | $1.5B | 13 |
| Current FY | $12.09 | $11.82–$12.17 | 8.2% | -0.0% | 11↑ 3↓ | $5.8B | 20 |
| Next FY | $13.23 | $12.74–$13.70 | 9.5% | +0.1% | 10↑ 2↓ | $6.2B | 20 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $2.669 | — |
| 7d ago | $2.676 | -0.008 |
| 30d ago | $2.688 | -0.020 |
| 60d ago | $2.827 | -0.159 |
| 90d ago | $2.851 | -0.183 |
Institutional ownership
Which big funds own RMD (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $15.4B total value (78,890,704 shares) as of 2026-Q2. Top holders: Erste, BlackRock,, VANGUARD. Net buying activity: 36 institutions added/increased vs 14 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Erste Asset Management GmbH | 0 | $0.00 | 0.0% | — |
| BlackRock, Inc. | 12,317,194 | $2.4B | 15.6% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 9,474,129 | $1.8B | 12.0% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7,913,661 | $1.5B | 10.0% | — |
| STATE STREET CORP | 6,680,735 | $1.3B | 8.5% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 4,352,320 | $845.2M | 5.5% | — |
| Bank of New York Mellon Corp | 4,197,610 | $818.0M | 5.3% | — |
| FIRST TRUST ADVISORS LP | 2,278,696 | $444.1M | 2.9% | ADD +48.2% |
| Invesco Ltd. | 2,063,578 | $402.1M | 2.6% | — |
| MORGAN STANLEY | 1,928,931 | $375.9M | 2.4% | TRIM -28.2% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FIRST TRUST ADVISORS LP | ADD | 1,537,825 | 2,278,696 | +48.2% | $444.1M |
| MORGAN STANLEY | TRIM | 2,686,821 | 1,928,931 | -28.2% | $375.9M |
| NORDEA INVESTMENT MANAGEMENT AB | ADD | 1,033,381 | 1,388,008 | +34.3% | $269.6M |
| UBS Group AG | ADD | 726,811 | 1,289,300 | +77.4% | $251.3M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | 450,250 | 1,129,739 | +150.9% | $220.2M |
| CITIGROUP INC | ADD | 390,082 | 774,425 | +98.5% | $150.9M |
| NORGES BANK | NEW | — | 664,714 | — | $129.5M |
| Amundi | TRIM | 1,062,184 | 604,304 | -43.1% | $117.8M |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | 179,288 | 600,983 | +235.2% | $117.1M |
| ALLIANCEBERNSTEIN L.P. | ADD | 380,448 | 491,472 | +29.2% | $110.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 30 transactions. Net -$13.2M — $0.00 bought, $13.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Farrell Michael J. | Chairman and CEO | EXERCISE | 4,991 | $146.34 | $730.4K |
| Sep 8, 2026 | Farrell Michael J. | Chairman and CEO | SELL | 4,991 | $222.44 | $1.1M |
| Sep 2, 2026 | FARRELL PETER C | Director | SELL | 970 | $234.73 | $227.7K |
| Aug 14, 2026 | Bloomer Aaron | Chief Financial Officer | AWARD | 9,072 | — | — |
| Aug 14, 2026 | Rider Michael J | Global General Counsel | AWARD | 3,230 | — | — |
| Aug 14, 2026 | Farrell Michael J. | Chairman and CEO | AWARD | 13,547 | — | — |
| Aug 14, 2026 | Leong Justin | Chief Product Officer | AWARD | 6,461 | — | — |
| Aug 7, 2026 | Farrell Michael J. | Chairman and CEO | EXERCISE | 4,991 | $146.34 | $730.4K |
| Aug 7, 2026 | Farrell Michael J. | Chairman and CEO | SELL | 4,991 | $205.69 | $1.0M |
| Aug 5, 2026 | FARRELL PETER C | Director | SELL | 8,000 | $225.00 | $1.8M |
Congressional trades
RMD trades disclosed by members of Congress, with disclosure delay.
2 members · 2 buys / 0 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Resmed Inc | May 13, 2026(31d) |
| Mar 27, 2026 | Alan Armstrong | R | SENATE | BUY | $1,001 - $15,000 | Resmed Inc | Jul 22, 2026(117d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for RMD.
Shares short
14,203,907
Settlement Sep 15, 2026
Change vs prior
+8.7%
Semi-monthly cycle
Days to cover
11.7
At avg daily volume
Of shares outstanding
≈9.8%
Estimate — not % of float
All RMD filing & press-release reports (11)
- CLUSTER reportSep 10, 2026
- CLUSTER reportAug 11, 2026
- PRESS-RELEASE reportJul 7, 2026
- PRESS-RELEASE reportJun 1, 2026
- PRESS-RELEASE reportMay 19, 2026
- CLUSTER reportApr 9, 2026
- CLUSTER reportApr 3, 2026
- PRESS-RELEASE reportApr 1, 2026
- CLUSTER reportMar 11, 2026
- CLUSTER reportMar 5, 2026
- INST-CLUSTER reportFeb 28, 2026